EGF Archive

October 12, 2018

Targeting diabetic kidney disease

Pathways activated by the epidermal growth factor receptor may be attractive targets to treat diabetic kidney disease, according to new findings from Vanderbilt investigators.

By Sanjay Mishra
May 18, 2017

Glowing receptors help find and track cancerous growth

Under the microscope, they sparkle like emeralds, these molecules that may hold a key to understanding — and stopping — cancerous growth.

By Bill Snyder
March 17, 2017

New target for colorectal cancer

Vanderbilt investigators have discovered that activated epidermal growth factor receptor may be a target for therapies to prevent colorectal cancer development.

By VUMC News and Communications
August 25, 2016

New fund honors spirit of Cohen’s innovative research

When Tom Daniel, M.D., joined the Vanderbilt University faculty in December 1986, Stanley Cohen, Ph.D., had just been awarded the Nobel Prize in Physiology or Medicine for his discovery of epidermal growth factor (EGF).

By Leigh MacMillan
October 10, 2013

Probing mutant EGF receptor regulation

Understanding the regulation of mutant EGF receptors commonly found in lung cancers could lead to new targeted therapies.

By Leigh MacMillan
June 6, 2013

VU study identifies new mechanism for cancer development

Researchers at Vanderbilt University Medical Center led by a 32-year-old postdoctoral fellow have discovered a new mechanism for the development of cancer that is challenging conventional scientific wisdom.

By Bill Snyder